Clinical trials: Antipsychotic
Mania, Schizophrenia
Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
With this observational study we want to examine if the intensity of agitation, the intensity of psychotic symptoms and the presence of sleeping disorder predict the success of the treatment with a atypical antipsychotic after 12…
- Trial name
- UPTAQE (NCT00534222)
- Where
- 6 sites in Netherlands
- Volunteers
- 387 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
The primary purpose of the study is to assess the safety and tolerability of a long-acting injectable formulation of risperidone when switching from an oral antipsychotic in patients with schizophrenia.
- Trial name
- NCT00034775
- Testing
- risperidone
- Volunteers
- 141 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dementia
Study of Depakote for Behavioral and Psychological Symptoms in Dementia
This prospective, naturalistic, open label study will test the hypothesis that Depakote is correlated with a reduction in elevated Cohen-Mansfield Agitation Index (CMAI) verbal and physical agitation and aggression scales over a…
- Trial name
- NCT00197834
- Testing
- Depakote
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hearthstone Alzheimer Care
Psychosis
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
To demonstrate the relative bioequivalency of generic Haloperidol tablets versus Haldol in normal volunteers.
- Trial name
- NCT00946491
- Testing
- Haloperidol 10 mg Tablets (Cord Laboratories), Haldol 10 mg Tablets (McNeil Pharmaceuticals)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Schizophrenia
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
The purpose of this study was to evaluate the efficacy of ASP4345 on cognitive impairment compared to placebo using change from baseline in MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score (excluding…
- Trial name
- NCT03557931
- Testing
- ASP4345, risperidone, quetiapine
- Where
- 27 sites in United States
- Volunteers
- 233 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Bipolar Disorder
Effectiveness of Anti-Psychotic in GPs Setting
Evaluating the effectiveness of atypical antipsychotics in the community - a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium
- Trial name
- Serenity (NCT00543088)
- Where
- 57 sites in Belgium
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Schizophrenia
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626859
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of paliperidone palmitate in schizophrenic inpatients who have experienced recent exacerbation of acute schizophrenia (that is within past 4 weeks).
- Trial name
- PREVAIL (NCT01527305)
- Testing
- Paliperidone palmitate
- Where
- 21 sites in China, Malaysia and 2 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Schizophrenia
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
The objective of this study is to evaluate under routine clinical setting the efficacy and remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute episode or not achieving remission under…
- Trial name
- QTP NIS (NCT00809731)
- Where
- 17 sites in Taiwan
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Schizophrenia
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
- Trial name
- NCT01295372
- Testing
- Zicronapine, Risperidone
- Where
- 24 sites in Czechia, Estonia and 3 more
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308 administered for 14 days in subjects with…
- Trial name
- NCT02037074
- Testing
- Drug: EVP-6308
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated.
- Trial name
- NCT00361166
- Testing
- ACP-103
- Where
- 17 sites in United States, Brazil
- Volunteers
- 400 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
AVE1625 is a new potent and selective cannabinoid 1 (CB1) antagonist in clinical development for the treatment of cognitive impairment in patients diagnosed with schizophrenia.
- Trial name
- CONNECT (NCT00439634)
- Testing
- AVE1625
- Where
- 2 sites in United States, Canada
- Volunteers
- 873 people
- Sponsor
- Sanofi
Bipolar Disorders
A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder
The purpose of this NIS is to obtain data on how AAPs are used in DSM-IV-TR Bipolar I and II Disorder, in the course of a major depressive episode.
- Trial name
- HARMONY (NCT00888264)
- Where
- 45 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
The purpose of the study is to assess the safety and effectiveness of risperidone (an antipsychotic medication) in adolescents with schizophrenia over 6 months of treatment.
- Trial name
- NCT00246285
- Testing
- risperidone
- Volunteers
- 381 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia and Schizoaffective Disorder
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
- Trial name
- NCT00347425
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- 122 sites in United States, Argentina and 7 more
- Volunteers
- 286 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia
Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
- Trial name
- NCT00073320
- Testing
- Paliperidone Palmitate
- Volunteers
- 88 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.